ArticleMolecular medicine (Cambridge, Mass.)2017
Development of a zebrafish sepsis model for high-throughput drug discovery.
Article in Molecular medicine (Cambridge, Mass.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 59 citations in OpenAlex.
- TNFα-dependent modulation of WT1-MMP9 regulatory axis links developmental and inflammatory pathways in glaucoma.iScience · 2026Article
- Dabigatran Prevents Lipopolysaccharide-Mediated Apoptosis in Zebrafish Through a Thrombin-Independent Mechanism.Shock (Augusta, Ga.) · 2026Article
- A teleost-specific oxygen-immunity axis where FIH activates NF-κB via competitive IκBα binding.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Spatially structured inflammatory response in the presence of a uniform stimulus.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The microbiome protects against septic hyperinflammation and bacterial proliferation in a zebrafish model of blood infection withFrontiers in immunology · 2026Article
- Multi-omics profiling reveals microbiota-gut-brain axis dysregulation in an LPS-induced model of sepsis-associated encephalopathy.Frontiers in cellular and infection microbiology · 2026Article
- Indole compounds produced by gut microbiota after metabolizing tryptophan improve dysmotility in sepsis via the AHR-TRPA1 axis in enteric nerves.BMC microbiology · 2025Article
- Phenotypic screening in influenza-infected zebrafish identifies Nrf2-mediated compound protective against ischemia-reperfusion injury.iScience · 2025Article
- Identification of Potential Sepsis Therapeutic Drugs Using a Zebrafish Rapid Screening Approach.Life (Basel, Switzerland) · 2024Article
- Targeting monocytic Occludin impairs transendothelial migration and HIV neuroinvasion.EMBO reports · 2024Article
- Plerixafor for pathogen-agnostic treatment in murine thigh infection and zebrafish sepsis.Clinical and translational science · 2024Article
- Understanding the pathophysiology of acute critical illness: translational lessons from zebrafish models.Intensive care medicine experimental · 2024Review
- High species homology potentiates quantitative inflammation profiling in zebrafish using immunofluorescence.Heliyon · 2024Article
- Exploiting the Zebrafish Model for Sepsis Research: Insights into Pathophysiology and Therapeutic Potentials.Drug design, development and therapy · 2024Review
- Article
- Article
- Tollip-deficient zebrafish display no abnormalities in development, organ morphology or gene expression in response to lipopolysaccharide.FEBS open bio · 2022Article
- The benefits, limitations and opportunities of preclinical models for neonatal drug development.Disease models & mechanisms · 2022Review
- Article
- Functional identification of the zebrafish Interleukin-1 receptor in an embryonic model of Il-1β-induced systemic inflammation.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a leading cause of death worldwide. Current treatment modalities remain largely supportive. Intervention strategies focused on inhibiting specific mediators of the inflammatory host response have been largely unsuccessful, a consequence of an inadequate understanding of the complexity and heterogeneity of the innate immune response. Moreover, the conventional drug development pipeline is time consuming and expensive and the low success rates associated with cell-based screens underline the need for whole organism screening strategies, especially for complex pathological processes. Here, we established an LPS-induced zebrafish endotoxemia model, which exhibits the major hallmarks of human sepsis including, edema and tissue/organ damage, increased vascular permeability and vascular leakage accompanied by an altered expression of cellular junction proteins, increased cytokine expression, immune cell activation and ROS production, reduced circulation and increased platelet aggregation. We tested the suitability of the model for phenotype-based drug screening using three primary readouts: mortality, vascular leakage, and ROS production. Preliminary screening identified fasudil, a drug known to protect against vascular leakage in murine models, as a lead hit thereby validating the utility of our model for sepsis drug screens. This zebrafish sepsis model has the potential to rapidly analyze sepsis associated pathologies and cellular processes in the whole organism, as well as to screen and validate large numbers of compounds that can modify sepsis pathology in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.